Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Insights into selected genetic diseases affecting the female reproductive tract and their implication for pathologic evaluation of gynecologic specimens.

Gwin K, Wilcox R, Montag A.

Arch Pathol Lab Med. 2009 Jul;133(7):1041-52. doi: 10.1043/1543-2165-133.7.1041. Review.

PMID:
19642731
2.

Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

Kauff ND, Barakat RR.

J Clin Oncol. 2007 Jul 10;25(20):2921-7. Review.

PMID:
17617523
3.

Screening and prevention of hereditary gynecologic cancers.

Kehoe SM, Kauff ND.

Semin Oncol. 2007 Oct;34(5):406-10. Review.

PMID:
17920895
4.

Management updates for women with a BRCA1 or BRCA2 mutation.

Nusbaum R, Isaacs C.

Mol Diagn Ther. 2007;11(3):133-44. Review.

PMID:
17570734
5.

[Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review].

Fruscalzo A, Lellé RJ, Calcagno A, Driul L, Damante G, Marchesoni D.

Minerva Ginecol. 2006 Apr;58(2):171-5. Review. Italian.

PMID:
16582871
6.

The predominant role of surgery in the prevention and new trends in the surgical treatment of women with BRCA1/2 mutations.

Fatouros M, Baltoyiannis G, Roukos DH.

Ann Surg Oncol. 2008 Jan;15(1):21-33. Epub 2007 Oct 17. Review.

PMID:
17940826
8.

BRCA1 and BRCA2 mutations in breast and ovarian cancer syndrome: reflection on the Creighton University historical series of high risk families.

Sinilnikova OM, Mazoyer S, Bonnardel C, Lynch HT, Narod SA, Lenoir GM.

Fam Cancer. 2006;5(1):15-20. Review.

PMID:
16528604
9.

Targeting the DNA repair defect of BRCA tumours.

Turner N, Tutt A, Ashworth A.

Curr Opin Pharmacol. 2005 Aug;5(4):388-93. Review.

PMID:
15955736
10.

Hereditary breast and ovarian cancers.

Carroll JC, Cremin C, Allanson J, Blaine SM, Dorman H, Gibbons CA, Grimshaw J, Honeywell C, Meschino WS, Permaul J, Wilson BJ.

Can Fam Physician. 2008 Dec;54(12):1691-2. Review. No abstract available.

11.

BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.

Palma M, Ristori E, Ricevuto E, Giannini G, Gulino A.

Crit Rev Oncol Hematol. 2006 Jan;57(1):1-23. Epub 2005 Dec 6. Review.

PMID:
16337408
12.

Modifiers of risk of hereditary breast and ovarian cancer.

Narod SA.

Nat Rev Cancer. 2002 Feb;2(2):113-23. Review.

PMID:
12635174
13.

[Recommendations for the management of women with an increased genetic risk of gynaecological cancer].

Verheijen RH, Boonstra H, Menko FH, de Graaff J, Vasen HF, Kenter GG.

Ned Tijdschr Geneeskd. 2002 Dec 14;146(50):2414-8. Review. Dutch.

PMID:
12518519
14.

Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

Casey MJ, Bewtra C, Hoehne LL, Tatpati AD, Lynch HT, Watson P.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. Review.

PMID:
10985881
15.

BAP1, a candidate tumor suppressor protein that interacts with BRCA1.

Jensen DE, Rauscher FJ 3rd.

Ann N Y Acad Sci. 1999;886:191-4. Review. No abstract available.

PMID:
10667217
16.

Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.

Liede A, Narod SA.

Hum Mutat. 2002 Dec;20(6):413-24. Review.

PMID:
12442265
17.

[Tumor risk consultation for predisposed women from high risk cancer families].

Beckmann MW, Niederacher D, Bodden-Heidrich R, Goecke TO, Kuschel B, Achnoula M, Aba F, Schnürch HG, Bender HG.

Praxis (Bern 1994). 1998 Apr 8;87(15):511-5. Review. German.

PMID:
9608246
18.

Recent advances in understanding of genetic susceptibility to breast cancer.

Stratton MR.

Hum Mol Genet. 1996;5 Spec No:1515-9. Review.

19.

Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.

Metcalfe KA, Foulkes WD, Kim-Sing C, Ainsworth P, Rosen B, Armel S, Poll A, Eisen A, Gilchrist D, Chudley A, Ghadirian P, Maugard C, Lemire EG, Sun P, Narod SA.

Clin Genet. 2008 May;73(5):474-9. doi: 10.1111/j.1399-0004.2008.00988.x. Epub 2008 Mar 12. Review.

PMID:
18341607
20.

Breast cancer susceptibility testing: past, present and future.

Goldberg JI, Borgen PI.

Expert Rev Anticancer Ther. 2006 Aug;6(8):1205-14. Review.

PMID:
16925486
Items per page

Supplemental Content

Write to the Help Desk